Iron protein succynilate in the treatment of iron deficiency: potential interaction with H2-receptor antagonists.
A prospective, open, multicenter clinical trial was set up to evaluate the potential interaction of ITF 282 with H2-receptor antagonists in patients affected with iron deficiency. Patients treated with H2 blockers and affected with iron deficiency or iron deficient anemia were given one tablet of ITF 282 (60 mg iron) twice daily for 60 days. A second group of iron deficient patients with no anti H2 concurrent treatment were admitted to the same iron treatment, lasting 60 days. To evaluate the outcome of the iron treatment, a comprehensive assessment of laboratory and clinical determinations was adopted in all the patients: special hematology, symptomatology, safety hematology and hematochemistry, urinalysis. Fifty-three patients with iron deficiency and 47 patients affected with overt iron deficient anemia entered the study. After treatment, a significant trend toward the normalization of the main hematologic parameters in both groups was detected. The general tolerability was apparently more favorable in the patients who had also the antiulcer (1 event of diarrhoea) than in those who had ITF 282 alone (2 heartburn, 3 constipation, 2 abdominal pain). There were no indications of subgroups of patients particularly at risk of adverse events, all of which resulted reversible without the need to reduce the dose of medication or to take other medical action. ITF 282 resulted, also when administered together with H2-receptor antagonists, in the expected therapeutic efficacy, with the expected clinical tolerability and biological safety, without signs of possible interaction, negative or positive.(ABSTRACT TRUNCATED AT 250 WORDS)
Bianchi
F M
FM
Department of Internal Medicine, Polyclinic Hospital S. Orsola-Malpighi, Bologna, Italy.
Cavassini
G B
GB
Leo
P
P
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000747:Anemia, Hypochromic / Q000097:blood / Q000188:drug therapy; D004347:Drug Interactions; D005260:Female; D005290:Ferric Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D006635:Histamine H2 Antagonists / Q000009:adverse effects*; D006801:Humans; D007501:Iron / Q000097:blood; D000090463:Iron Deficiencies; D008297:Male; D008667:Metalloproteins / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D011446:Prospective Studies; D013386:Succinates / Q000009:adverse effects* / Q000627:therapeutic use
D005290:Ferric Compounds; D006635:Histamine H2 Antagonists; D008667:Metalloproteins; D013386:Succinates; D007501:Iron; C055066:iron protein succinylate